Conformis Product Revenue Battered by Procedure Delays

Conformis reported 3Q21 orthopedic revenue of $14.3 million, -11.6% vs. 3Q20. The company expects a modest sequential improvement from the second quarter, but Delta-related procedure drop-offs proved higher than expected from mid-August through the end of the quarter.

Healthy system staffing shortages have widened the reschedule window for...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us